Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.75
Bid: 41.50
Ask: 42.00
Change: -1.45 (-3.36%)
Spread: 0.50 (1.205%)
Open: 42.75
High: 42.75
Low: 41.50
Prev. Close: 43.20
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

Mon, 19th Jun 2023 07:53

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

"With some US markets closed for the Juneteenth public holiday, today's European session is likely to be a quiet one, with a modestly negative open after US markets finished the end of a positive week, with their first daily decline in six days," CMC Markets analyst Michael Hewson commented.

The pound was on the front foot ahead of the Bank of England's interest rate decision on Thursday, with Threadneedle Street expected to enact a 25 basis point hike. There will be UK inflation data on Wednesday, ahead of the BoE decision.

There will also be interest rate decisions from the People's Bank of China on Tuesday, and the Swiss National Bank on Thursday.

Meanwhile, US Secretary of State Blinken met with his Chinese counterpart Qin Gang at the start of his two-day trip to Beijing, a visit aimed at rebuilding the cratering relationship between the world's two largest economies.

A series of meetings with high-ranking government representatives are planned before Blinken - the most senior US official to visit China in years - leaves on Monday. It remains unclear whether he will meet with Chinese leader Xi Jinping.

In early UK economic news, house prices fell marginally in June, according to Rightmove. In company news, AstraZeneca is said to be mulling a spin-off of its Chinese business. The UK competition watchdog said it is eyeing up Severn Trent's acquisition of a food waste anaerobic digestion plant operator.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 34.0 points, 0.4%, at 7,608.72

----------

Hang Seng: down 1.1% at 19,815.13

Nikkei 225: closed down 0.9% at 33,400.47

S&P/ASX 200: closed up 0.6% at 7,294.90

----------

DJIA: closed down 108.94 points, 0.3%, at 34,299.12

S&P 500: closed down 0.4% at 4,409.59

Nasdaq Composite: closed down 0.7% at 13,689.57

----------

EUR: up at USD1.0941 (USD1.0926)

GBP: up at USD1.2825 (USD1.2819)

USD: up at JPY141.63 (JPY141.59)

GOLD: down at USD1,955.50 per ounce (USD1,960.83)

OIL (Brent): down at USD75.45 a barrel (USD75.62)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

US Juneteenth holiday. Financial markets closed.

11:00 BST Ireland goods exports and imports

----------

UK MPs vote Monday on a damning report that found ex-prime minister Boris Johnson deliberately lied to parliament about lockdown-breaking parties, in what the government hopes will be the final chapter in the damaging "Partygate" scandal. The parliamentary vote is being held on Johnson's 59th birthday as the wounded former leader ponders his next move, with allies predicting a future return to the electoral fray. It also comes at a time of mounting political problems for Rishi Sunak's Conservative government, as stubbornly high inflation and constantly rising interest rates inflict economic pain on voters.

----------

UK house prices suffered a marginal fall this month, the first June decline since 2017, according to a Rightmove tracker. Average new seller asking prices fell by just GBP82 in June to GBP372,812 from GBP372,894. Prices had risen 1.8% in May from April. Though fractional, June's outturn was the first monthly drop in asking prices this year. It was the first June fall in house prices since 2017. The outlook for house prices is less-than-stellar too, Rightmove predicts. The property portal expects asking prices to fall in most months for the rest of the year, in line with season patterns. Rightmove still predicts UK house prices to decline by 2% over the whole of 2023. Mortgage rates have increased recently, though Rightmove noted buyer demand has not been hurt. Demand over the last two weeks was 6% higher than in pre-pandemic 2019.

----------

BROKER RATING CHANGES

----------

Redburn raises Entain to 'buy' from 'neutral'

----------

HSBC raises Fevertree Drinks to 'buy' - price target 1,600 pence

----------

Deutsche Bank cuts Asos price target to 485 (725) pence - 'hold'

----------

COMPANIES - FTSE 100

----------

AstraZeneca has drafted plans to separate its China business amid geopolitical tensions, the Financial Times reported. The company is aiming to shield itself from simmering tensions between China, the world's second-largest economy, and the West. The FT, citing people familiar with the matter, reported that the Cambridge, England-based pharmaceutical company began discussing the idea with bankers "several months ago". It is among a growing number of multinational companies now considering that option, the FT added. A move may ultimately not take place, the FT sources said, though a Shanghai listing is also possible. The Chinese market is an attractive one for pharma firms, as the nation has an ageing population and as the government there speeds up the regulatory process for innovative medicines.

----------

The UK Competition & Markets Authority said it was looking at Severn Trent's acquisition of Andigestion to see whether it would lessen competition in the UK market. Back in February, the water utility had announced its green power unit's acquisition of Andigestion, which operates two food waste anaerobic digestion plants in southwest England. It said it expected the purchase to add another 45 gigawatt hours per year to its energy generation. "To assist it with this assessment, the CMA invites comments on the transaction from any interested party," the regulator said.

----------

Coca-Cola HBC announced it will acquire Brown-Forman Finland, which owns the Finlandia vodka brand, from Brown-Forman's Dutch subsidiary. It will pay USD220 million, and expects the acquisition to complete in the second half. It is subject to regulatory approvals. "Having been associated with the distribution of Finlandia for 17 years in several markets, we are excited by this unique and regionally relevant opportunity that will support the acceleration of our on-premise business across more of our markets," said Chief Executive Zoran Bogdanovic.

----------

COMPANIES - FTSE 250

----------

IT services provider Kainos said its CEO of 22 years, Brendan Mooney, will finish his term in the role by the end of September, with Digital Services Director Russell Sloan replacing him. Mooney will remain "actively engaged" with the business until next June, to ensure an orderly transition. "Brendan and Russell have worked closely as colleagues for many years and today formalises the final stage of our four-year succession process," said Chair Tom Burnet.

----------

RHI Magnesita received a partial cash offer for 30% of its shares from Ignite Luxembourg Holdings, a company indirectly managed by Rhone Holdings VI. Rhone is now offering GBP28.50 per share for 29.9% of the company. In late May, Rhone made a tilt for a 20% stake in the Vienna-based supplier of refractory products, also at GBP28.50 per share. At that time, it had said it reserved the right to increase the offer size to up to 29.9%. RHI Magnesita had said in May that its board was "considering its response to the partial offer and a further announcement will be made in due course".

----------

OTHER COMPANIES

----------

Life sciences firm Avacta Group denied media reports of plans for an imminent fundraising. "The company regularly considers potential funding opportunities, both non-dilutive and dilutive, to ensure its business operations remain well financed and the best interests of its stakeholders are maintained," it explained. Avacta said whilst it "[maintains] a dialogue" with shareholders and current investors, "no fundraising is imminent". It had cash of GBP27 million on the balance sheet at the end of May, and expects "strong news flow" in the coming months across the company.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
5 Sep 2022 07:16

Avacta's soft tissue sarcoma treatment gets FDA orphan drug designation

(Sharecast News) - Biotechnology company Avacta Group said on Monday that its soft tissue sarcoma treatment has been granted orphan drug designation by the US Food and Drug Administration.

Read more
1 Sep 2022 12:01

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort.

Read more
21 Jul 2022 15:29

Avacta joint venture completes fresh funding round

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.

Read more
21 Jul 2022 12:17

Avacta joint venture completes funding for lead cell therapy programme

(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round.

Read more
30 Jun 2022 11:22

Avacta's partner LG Chem renews licence to develop Affimer platform

(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta.

Read more
29 Jun 2022 11:38

AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
29 Jun 2022 10:21

Avacta shares up as cancer drug AVA6000 advances to third dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort.

Read more
16 Jun 2022 16:03

UK shareholder meetings calendar - next 7 days

Friday 17 June 
Blackstone Loan Financing LtdAGM
boohoo Group PLCAGM
Directa Plus PLCAGM
Tesco PLCAGM
EnQuest PLCAGM
Octopus Renewables Infrastructure Trust PLCAGM
Monday 20 June 
Armadale Capital PLCAGM
Bank of Georgia Group PLCAGM
Globalworth Real Estate Investments LtdAGM
MetalNRG PLCAGM
Midatech Pharma PLCAGM
Silver Bullet Data Services Group PLCGM re fundraise
Venture Life Group PLCAGM
Tuesday 21 June 
1Spatial PLCAGM
Altus Strategies PLCAGM
Coca-Cola HBC AGAGM
FireAngel Safety Technology Group PLCAGM
HC Slingsby PLCAGM
HSS Hire Group PLCAGM
Mission Group PLCAGM
Novacyt SAAGM
Pendragon PLCAGM
RTW Venture Fund LtdAGM
Velocys PLCAGM
Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Zinnwald Lithium PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
16 May 2022 14:04

IN BRIEF: Avacta joint venture expands partnership with GenScript

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partnership covers the process development and production of viral vectors required for the production of AffyXell's future cell therapy products. Adds that GenScript has now committed to take an equity position in AffyXell at a future funding round. The two companies will also collaborate in the area of business development, including potential out-licensing.

Read more
13 Apr 2022 17:33

Avacta increases shareholding in drug developer AffyXell to 22%

(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.

Read more
13 Apr 2022 13:57

Avacta triggers milestone in Daewoong joint venture

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Wednesday that a milestone equity payment has been triggered, resulting in an increase in its shareholding in AffyXell Therapeutics.

Read more
8 Apr 2022 16:17

Avacta joint venture enters new immune model collaboration

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

Read more
8 Apr 2022 11:28

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
8 Apr 2022 10:37

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

Read more
6 Apr 2022 10:23

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.